BioNTech said Thursday that it expected its COVID-19 vaccine, jointly developed with Pfizer, to be available to 12-to-15-year-olds in Europe from June.
BioNTech said Thursday that it expected its COVID-19 vaccine, jointly developed with Pfizer, to be available to 12-to-15-year-olds in Europe from June.
